Your browser doesn't support javascript.
loading
Stroke risk related to intentional discontinuation of antithrombotic therapy for invasive procedures.
Mitsui, Nobuyuki; Kinoshita, Manabu; Sawada, Jun; Fujiya, Mikihiro; Furukawa, Hiroyuki.
Afiliação
  • Mitsui N; 1Department of Neurosurgery, Asahikawa Medical University.
  • Kinoshita M; 1Department of Neurosurgery, Asahikawa Medical University.
  • Sawada J; 2First Department of Internal Medicine, Division of Neurology, Asahikawa Medical University.
  • Fujiya M; 3Department of Medicine, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Asahikawa Medical University.
  • Furukawa H; 4Medical Security and Safety Management Department, Asahikawa Medical University; and.
Neurosurg Focus ; 55(4): E7, 2023 10.
Article em En | MEDLINE | ID: mdl-37778043
ABSTRACT

OBJECTIVE:

Antithrombotic medications pose a challenge for conducting surgical or invasive procedures, because their discontinuation is required to avoid postprocedural hemorrhagic complications but potentially increases the ischemic risk for the patient. This study aimed to estimate the increased risk of developing cerebral ischemic events during hospitalization requiring discontinuation of antithrombotic therapy.

METHODS:

This investigation was a single-center retrospective observational study. Clinical data in patients scheduled for admission between January 1, 2021, and December 31, 2022, were collected. Patients requiring discontinuation of antithrombotic therapy were identified by referring to the admission database. Patients who developed cerebral ischemia were identified by referring to the institution's stroke center database.

RESULTS:

Seven hundred ninety-six patients scheduled for nonneurosurgical procedures and 39 scheduled for neurosurgical procedures underwent discontinuation of antithrombotic therapy. Anticoagulation therapy was prescribed in 40.0%, and antiplatelet therapy was prescribed in 69.1% of the patients. A total of 9.2% of the entire cohort of patients were receiving both anticoagulation and antiplatelet therapy. Bridging therapy was administered in 20.9% of nonneurosurgical patients. No ischemic event was observed in the patients undergoing neurosurgical procedures. Among the entire cohort, 3 patients encountered some kind of thrombotic event-2 of which were cerebral ischemia-accounting for an incidence of 0.24%, which was significantly higher than incidental in-hospital stroke unrelated to discontinuation of antithrombotic therapy (p = 0.04). Patients undergoing both anticoagulation and antiplatelet therapy harbored a significantly higher risk for cerebral ischemia related to discontinuation of antithrombotic therapy (p < 0.0001).

CONCLUSIONS:

Discontinuing antithrombotic therapy during hospitalization for elective invasive procedures-including neurosurgical procedures-entailed a relatively small risk of developing cerebral ischemic events, but the risk was significantly higher compared to hospitalized patients without discontinuation of antithrombotic therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Isquemia Encefálica / Acidente Vascular Cerebral Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Neurosurg Focus Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Isquemia Encefálica / Acidente Vascular Cerebral Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Neurosurg Focus Ano de publicação: 2023 Tipo de documento: Article